Antibodies specific for human cripto-related polypeptide CR-3

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

5303897, 4241381, 4241391, 4241551, 4241741, A61K 39395

Patent

active

058543996

ABSTRACT:
The present invention relates, in general, to a human CRIPTO-related gene. In particular, the present invention relates to a DNA segment encoding a human CRIPTO-related gene; polypeptides encoded by said DNA segment; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing a human CRIPTO-related polypeptide; a DNA segment encoding a genomic clone of the human CRIPTO gene (CR-1); antibodies specific to CR-3; and a method of measuring the amount of CR-3 in a sample.

REFERENCES:
Ciccodicola, Alfredo, et al. (1989) "Molecular characterization of a gene of the `EGF family` expressed in undifferentiated human NTERA2 teratocarcinoma cells", The EMBO Journal, 8:1987-1991.
Romkes et al. Biochemistry vol. 30:3247-3255 1991.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antibodies specific for human cripto-related polypeptide CR-3 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies specific for human cripto-related polypeptide CR-3, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies specific for human cripto-related polypeptide CR-3 will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1425891

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.